
Annual report 2025
added 04-04-2026
InMode Ltd. EBITDA 2011-2026 | INMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA InMode Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.1 M | 113 M | 196 M | 199 M | 168 M | 73.3 M | 59.9 M | 23.7 M | 9.15 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 9.15 M | 103 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
437 M | $ 36.74 | - | $ 5.47 K | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 9.38 | - | $ 266 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.59 | - | $ 36.7 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.07 | - | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 9.7 | - | $ 347 M | ||
|
EDAP TMS S.A.
EDAP
|
-17.9 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 81.19 | - | $ 47.5 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.6 | - | $ 122 M | ||
|
Globus Medical
GMED
|
757 M | $ 88.6 | - | $ 12 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.9 | - | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 54.14 | - | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | - | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.63 | - | $ 2.97 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.94 | - | $ 374 M | ||
|
LENSAR
LNSR
|
-21 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 86.28 | - | $ 111 B | ||
|
Align Technology
ALGN
|
753 M | $ 171.87 | - | $ 12.9 B | ||
|
Myomo
MYO
|
-13.5 M | $ 0.7 | - | $ 29.3 M | ||
|
AxoGen
AXGN
|
-1.19 M | $ 32.64 | - | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 11.77 | - | $ 466 M | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Penumbra
PEN
|
207 M | $ 329.87 | - | $ 12.8 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
564 M | $ 203.5 | - | $ 14.3 B | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.53 | 0.4 % | $ 7.02 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.13 | -0.24 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Smith & Nephew plc
SNN
|
1.16 B | $ 32.63 | - | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
6.46 B | $ 332.3 | - | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
35.9 M | $ 24.57 | - | $ 562 M | ||
|
TELA Bio
TELA
|
-33.1 M | $ 0.63 | 5.47 % | $ 29.6 M | ||
|
TransMedics Group
TMDX
|
136 M | $ 104.8 | - | $ 3.56 B | ||
|
Tandem Diabetes Care
TNDM
|
26 M | $ 19.17 | - | $ 1.3 B | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M |